Izvorni znanstveni članak
https://doi.org/10.2478/aiht-2022-73-3608
Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL/6 mice
David Jutrić
; 1 University of Zagreb Faculty of Science, Zagreb, Croatia 2 Clinical Hospital Dubrava, Zagreb, Croatia
Domagoj Đikić
; University of Zagreb Faculty of Science, Zagreb, Croatia
Almoš Boroš
; University of Zagreb Faculty of Science, Zagreb, Croatia
Dyna Odeh
; University of Zagreb Faculty of Science, Zagreb, Croatia
Sandra Domjanić Drozdek
; University of Applied Health Sciences, Zagreb, Croatia
Romana Gračan
; University of Zagreb Faculty of Science, Zagreb, Croatia
Petar Dragičević
; University of Zagreb School of Medicine, Zagreb Croatia
Irena Crnić
; University of Zagreb Faculty of Food Technology and Biotechnology, Zagreb, Croatia
Irena Landeka Jurčević
; University of Zagreb Faculty of Food Technology and Biotechnology, Zagreb, Croatia
Sažetak
Valproate is a common antiepileptic drug whose adverse effects include liver steatosis and dyslipidaemia. The aim of our study was to see how natural flavonoid antioxidant naringin would interact with valproate and attenuate these adverse effects. For this reason we treated male C57BL/6 mice with a combination of 150 mg/kg of valproate and 25 mg/kg naringin every day for 10 days and compared their serum triglycerides, cholesterol, LDL, HDL, VLDL, and liver PPAR-alpha, PGC-1 alpha, ACOX1, Nrf2, SOD, CAT, GSH, and histological signs of steatosis. Valproate increased lipid peroxidation parameters and caused pronounced microvesicular steatosis throughout the hepatic lobule in all acinar zones, but naringin co-administration limited steatosis to the lobule periphery. In addition, it nearly restored total serum cholesterol, LDL, and triglycerides and liver ACOX1 and MDA to control levels. and upregulated PPAR-alpha and PGC-1 alpha, otherwise severely downregulated by valproate. It also increased SOD activity. All these findings suggest that naringin modulates key lipid metabolism regulators and should further be investigated in this model, either alone or combined with other lipid regulating drugs or molecules.
Ključne riječi
ACOX1; cholesterol; dyslipidaemia; lipid regulating transcription factors; Nrf2; oxidative stress; PPAR-alpha; PGC-1 alpha
Hrčak ID:
274567
URI
Datum izdavanja:
30.3.2022.
Posjeta: 766 *